Menu
We are committed to providing sustainable, easy to use, medical grade digital solutions that help patients take control of their health.
We believe that our customers’ needs always come first, so we strive to provide the most advanced technological solutions based on trust, business integrity and long-term commitment. Health care professionals trust us to deliver solutions and performance that enable them to do vital work for their patients.
Our leadership team is dedicated to excellence in everything from solution development to patient experience, accountability, and fostering a spirit of daring and innovation. Cordio Medical’s Management leads a team of experts who apply a patient-centric approach to innovative solutions.
Tamir joins Cordio Medical with over 20 years experience in operations, finance, business development and management of multiple high-tech companies. Tamir started his career as a corporate lawyer with Shiboleth LLP where he focused on hi-tech sector securities transactions, IPO, M&A and venture capital investments. He later served as COO at Neovasc Medical Ltd., a cardiovascular medical device company that developed the Neovasc Reducer™ for the treatment of refractory angina (NASDAQ: (NVCN) as well as COO at of Geomage a leading provider of imaging solution for the oil and gas industry. Since 2005, Tamir has held the position of Venture Partner at Peregrine Ventures.
For more than 35 years Ilan has been at the forefront of speech signal processing and was an essential figure in developing numerous successful applications both for military intelligence and commercial markets. In 1985, Ilan joined DSP and served as the Director of the Speech Processing Group and led a large team of engineers to develop and implement DSP’s speech recognition products worldwide. In 1993, Ilan founded NSC, a global company that developed and sold speech recognition products for telephony networks. The company was later acquired by AudioCodes (NASDAQ: (AUDC). Ilan holds a PhD in Electrical and Computer Engineering from Ben-Gurion University.
Ronit has over two decades of experience in Clinical Trials, both in the scientific side and in operations. Early in her career, she served as Head of the Clinical Department of two large international pharmaceutical companies, MSD and Actelion. During her career she served as Director & Clinical Leader in Teva R&D department. Ronit joined Cordio Medical in 2018 as a Sr VP Clinical, QA and RA. Ronit holds a PhD in Life Sciences from Tel-Aviv University.
Itai has 15 year of experience in research, algorithm development and speech processing. Itai previously served as Director of Algorithms for Agrint, a start-up developing sensors for tree pest detection. Prior to Agrint, Itai was a Team Leader of Media Technology and Signal Processing at AudioCodes, leading research and development in the fields of automatic speech recognition, VoIP, and speech quality analysis and monitoring. In 2018, Itai joined Cordio Medical as VP R&D, leading and conducting algorithm research and development from POC to product. Itai holds a BSc. (Cum Laude) in Electrical engineering from BGU and an MSc. In Electrical engineering from Technion.
Leon brings with him more than 25 years’ experience in the high-tech industry with a focus on speech processing technologies. Prior to Cordio Medical, Mr. Eting served as Director Business Development VAS at Audiocodes. Mr. Eting also served as the CEO and Founder of HOTAS, a start-up company that developed, manufactured and sold voice activated wireless communication products for the automotive market. Mr. Eting was a fighter pilot in the Israeli Air Force. He holds a B.Sc. in Physics and Computer Science from Bar-Ilan University, Israel, and an MBA from INSEAD Business School (Fontainebleau, France).
Lior has over 20 years’ experience in leading and managing full-stack R&D Groups of SaaS products. Lior brings with him extensive experience in implementing cutting edge R&D Processes, Back-end technologies, Large Scale systems, system architecture, as well as Data Science and Algorithms development leadership. Lior started his career as a software developer in the elite IDF Technology unit (MAMRAM), where he focus on developing C&C systems. Following his work for the IDF, he served as R&D Team Leader at c-nario, a startup that developed video technologies and content management systems. Lior held various senior management positions for global companies such as Voyager Analytics, Welltika and NICE.
Stavit Cohen is a highly accomplished executive serving as the Senior Vice President of Research and Development at Cordio Medical. With an illustrious career marked by leadership roles at prominent companies in the medical technology sector, Ms. Cohen possesses a wealth of experience in driving R&D initiatives at a senior leadership level. Her expertise lies in fostering innovation and establishing the foundation for high-performing R&D organizations through the implementation of best-in-class practices and methodologies.
In her current role at Cordio Medical, Ms. Cohen has been instrumental in advancing medical technologies, contributing to the company’s growth and success.
Ms. Cohen has served as the Senior Vice President of Research and Development, focusing on cutting-edge technologies, including surgical robotics in Momentis Surgical. Her leadership in the field of Cardiovascular, Heart Failure and Electrophysiology technologies has been a consistent theme throughout her career.
Prior to her current position, Ms. Cohen held key positions at Philips, where she served as Senior Director of R&D and Site Leader. In this capacity, she played a crucial role in the adoption of technology, spearheaded M&A activities, and established strategic partnerships, notably with Medtronic, Inc.
Ms. Cohen’s career journey also includes various roles at Abbott Laboratories, where she steadily progressed to become R&D Leader, Site Leader, and ultimately, Chief Executive Officer of MediGuide, Inc. The latter was successfully acquired by St. Jude Medical, Inc. in 2008, subsequently becoming part of Abbott in 2017.
Ms. Cohen is a distinguished alumna of Technion – Israel Institute of Technology, holding both an MBA and a Bachelor of Science degree in computer science. Her academic background, combined with her extensive professional experience, positions her as a dynamic leader in the field of medical technology, driving innovation and success in every role she undertakes.
Eyal Lifschitz, General Partner and Co-Founder of Peregrine Ventures. On behalf of the Fund, Eyal serves on the Boards of many of the portfolio companies, including Valtech Cardio, NLT Spine, and CardioNova. Prior to founding Peregrine Ventures, Eyal co-founded and led the business development efforts of a number of medical technology companies including PharmaSys (acquired by Elan Corp. NYSE:ELN), ECR (acquired by AVX Corp. NYSE:AVX), Visioncare Ophthalmic Technologies, and BioControl Ltd. From 2003-2007 Eyal also served as a Director of Given Imaging (NASDAQ: GIVN).
Prof. Lotan has served as Director of Interventional Cardiology at Hadassah Medical Center, has as the Director of the Hadassah Heart Institute since September 2000 and Head of the Cardiovascular Division since 2015. He is a Professor of Medicine in Cardiology at The Hebrew University, and in 2004, he established the Hadassah Cardiovascular Research Center. Prof. Lotan founded the Israeli Working Group for Interventional Cardiology in Israel and served as its Secretary General for 4 years. He served as President of the Israel Heart Society in 2011-2013. He is the chairman of the Committee for Certification & Licensing of Coronary Stents in the Israel Ministry of Health. He has, in addition, participated in various research projects and initiated and directed many study protocols, and continues to do so. He also serves as a consultant to several startup companies. He is Course Co-Director of the international scientific congress “Innovations in Cardiovascular Interventions (ICI)” held in Israel. Prof. Lotan completed his medical training in Medicine and Cardiology at the Hadassah-Hebrew University Medical Center.
Lior brings extensive experience and expertise in investments due diligence, strategic planning, project management and business development. Working closely with entrepreneurs to establish successful companies. Since joining Peregrine in 2005, Lior has served as CEO of Incentive, Peregrine’s technology incubator. Under his leadership Incentive has received 7 excellence awards by the state of Israel for its performance and made 7 exits (Valtech, Neovasc, Bballoon, NLT spine, Eurekify, Marketyze, Rocketick). Lior holds a BA in Economics and Business Management from the University of Haifa and an MBA from Tel-Aviv University.
Sandra Morgan is an accomplished senior executive with a record of consistent growth and results. During her 32 years in healthcare, she worked for Fortune 100 companies, including HCA Healthcare and Pfizer. Ms. Morgan retired from HCA as senior vice president, provider relations, in June 2021.
At HCA Healthcare, Ms. Morgan built a world-class provider relations organization with record- high growth and physician engagement. She led teams working across multiple areas to achieve financial objectives by attracting and retaining non-employed physician customers while increasing their engagement and fulfilling the company’s mission for the care and improvement of human life. She spearheaded the enterprise transfer center and employer broker solutions organizations, and founded the Management Development Group, resulting in many of the company’s exceptional leaders. Her responsibilities also included compliance, developing a customer relations management system, and customer analytic tools. Her teams’ focus was growing business for HCA Healthcare’s hospitals, surgery centers, urgent care clinics, behavioral health programs, and all service lines, including a special focus on surgery and robotics.
Earlier in her career, Ms. Morgan worked extensively in the pharmaceutical industry for 19 years, with her last role as vice president for Pfizer’s US managed care business. She played a major role in the initial launch of products while achieving formulary status for Pfizer’s extensive portfolio.
Ms. Morgan earned a B.S. degree in business administration from the University of Illinois and an M.B.A. from St. Joseph’s University.
